{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:33:22Z","timestamp":1764858802240},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.canlet.2015.02.031","type":"journal-article","created":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T17:48:08Z","timestamp":1424108888000},"page":"245-256","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Restoration of miR-424 suppresses BCR\u2013ABL activity and sensitizes CML cells to imatinib treatment"],"prefix":"10.1016","volume":"360","author":[{"given":"Oshrat","family":"Hershkovitz-Rokah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shira","family":"Modai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metsada","family":"Pasmanik-Chor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amos","family":"Toren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noam","family":"Shomron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galit","family":"Granot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2015.02.031_bib0010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cell.2009.04.040","article-title":"SnapShot: MicroRNAs in cancer","volume":"137","author":"Spizzo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2015.02.031_bib0015","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.leukres.2005.09.001","article-title":"Hematopoietic-specific microRNA expression in human cells","volume":"30","author":"Ramkissoon","year":"2006","journal-title":"Leuk. Res"},{"key":"10.1016\/j.canlet.2015.02.031_bib0020","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2015.02.031_bib0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/bcr2484","article-title":"MicroRNAs and their target gene networks in breast cancer","volume":"12","author":"O'Day","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.canlet.2015.02.031_bib0030","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/01243894-200611000-00002","article-title":"MicroRNA in lung cancer","volume":"1","author":"Nana-Sinkam","year":"2006","journal-title":"J. Thorac. Oncol"},{"key":"10.1016\/j.canlet.2015.02.031_bib0035","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.22757","article-title":"MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma","volume":"49","author":"Li","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.02.031_bib0040","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1016\/j.ejca.2010.06.127","article-title":"MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells","volume":"46","author":"Xu","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2015.02.031_bib0045","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1158\/0008-5472.CAN-05-0137","article-title":"MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells","volume":"65","author":"Chan","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.02.031_bib0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-4598-5-29","article-title":"Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues","volume":"5","author":"Bandres","year":"2006","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2015.02.031_bib0055","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/sj.onc.1210186","article-title":"MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia","volume":"26","author":"Garzon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.02.031_bib0060","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1590\/S0100-879X2007001100003","article-title":"miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia","volume":"40","author":"Zanette","year":"2007","journal-title":"Braz. J. Med. Biol. Res"},{"key":"10.1016\/j.canlet.2015.02.031_bib0065","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2015.02.031_bib0070","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.02.031_bib0075","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate \u2013 a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2015.02.031_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-07-0573","article-title":"MicroRNAs modulate the chemosensitivity of tumor cells","volume":"7","author":"Blower","year":"2008","journal-title":"Mol. Cancer Ther"},{"key":"10.1016\/j.canlet.2015.02.031_bib0085","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1535-7163.MCT-09-0127","article-title":"Correcting miR-15a\/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity","volume":"8","author":"Salerno","year":"2009","journal-title":"Mol. Cancer Ther"},{"key":"10.1016\/j.canlet.2015.02.031_bib0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1479-5876-11-265","article-title":"MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1","volume":"11","author":"Zhou","year":"2013","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.canlet.2015.02.031_bib0095","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.molcel.2011.08.021","article-title":"MicroRNA destabilization enables dynamic regulation of the miR-16 family in response to cell-cycle changes","volume":"43","author":"Rissland","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2015.02.031_bib0100","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1093\/nar\/gkn522","article-title":"miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes","volume":"36","author":"Liu","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.canlet.2015.02.031_bib0105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/leu.2009.246","article-title":"Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation","volume":"24","author":"Forrest","year":"2010","journal-title":"Leukemia"},{"issue":"2 Pt B","key":"10.1016\/j.canlet.2015.02.031_bib0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.canlet.2014.10.006","article-title":"MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein","volume":"356","author":"Hershkovitz-Rokah","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2015.02.031_bib0115","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.leukres.2012.12.003","article-title":"Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia","volume":"37","author":"Liu","year":"2013","journal-title":"Leuk. Res"},{"key":"10.1016\/j.canlet.2015.02.031_bib0120","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.yexcr.2013.02.002","article-title":"miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR\/ABL1 protein","volume":"319","author":"Li","year":"2013","journal-title":"Exp. Cell Res"},{"key":"10.1016\/j.canlet.2015.02.031_bib0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/onc.2012.557","article-title":"BCR-ABL\/GATA1\/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia","volume":"33","author":"Xu","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.02.031_bib0130","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","article-title":"Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth","volume":"6","author":"Agirre","year":"2008","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.canlet.2015.02.031_bib0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12079-011-0139-x","article-title":"MicroRNAs 130a\/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML","volume":"5","author":"Suresh","year":"2011","journal-title":"J. Cell. Commun. Signal"},{"key":"10.1016\/j.canlet.2015.02.031_bib0140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00277-010-1072-4","article-title":"Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia","volume":"90","author":"Hussein","year":"2011","journal-title":"Ann. Hematol"},{"key":"10.1016\/j.canlet.2015.02.031_bib0145","doi-asserted-by":"crossref","first-page":"e35501","DOI":"10.1371\/journal.pone.0035501","article-title":"Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells","volume":"7","author":"Rokah","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.02.031_bib0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2012.03.021","article-title":"How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages","volume":"322","author":"Breccia","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2015.02.031_bib0155","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2015.02.031_bib0160","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1038\/sj.onc.1205653","article-title":"Killing of leukemic cells with a BCR\/ABL fusion gene by RNA interference (RNAi)","volume":"21","author":"Wilda","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.02.031_bib0165","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood-2002-12-3899","article-title":"Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)","volume":"102","author":"Wohlbold","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.02.031_bib0170","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2009.016063","article-title":"Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib","volume":"95","author":"Koldehoff","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2015.02.031_bib0175","first-page":"560","article-title":"MicroRNAs: small but potent oncogenes or tumor suppressors","volume":"7","author":"Lee","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.canlet.2015.02.031_bib0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00063030-200923010-00002","article-title":"MicroRNA-based therapeutics for cancer","volume":"23","author":"Wang","year":"2009","journal-title":"Biodrugs"},{"key":"10.1016\/j.canlet.2015.02.031_bib0185","doi-asserted-by":"crossref","first-page":"e91661","DOI":"10.1371\/journal.pone.0091661","article-title":"MicroRNA-424 is down-regulated in hepatocellular carcinoma and suppresses cell migration and invasion through c-Myb","volume":"9","author":"Yu","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.02.031_bib0190","doi-asserted-by":"crossref","first-page":"e80300","DOI":"10.1371\/journal.pone.0080300","article-title":"MiR-424\/503-mediated Rictor upregulation promotes tumor progression","volume":"8","author":"Oneyama","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.02.031_bib0195","doi-asserted-by":"crossref","first-page":"825","DOI":"10.6061\/clinics\/2013(06)17","article-title":"Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells \u2013 Cdc2 activity is up-regulated by targeting WEE1","volume":"68","author":"Chen","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.canlet.2015.02.031_bib0200","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3892\/etm.2013.959","article-title":"Tumor suppressive microRNA-424 inhibits osteosarcoma cell migration and invasion via targeting fatty acid synthase","volume":"5","author":"Long","year":"2013","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.canlet.2015.02.031_bib0205","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12253-013-9637-x","article-title":"MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer","volume":"19","author":"Wu","year":"2013","journal-title":"Pathol. Oncol. Res"},{"key":"10.1016\/j.canlet.2015.02.031_bib0210","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.4161\/cc.21278","article-title":"Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm","volume":"11","author":"Cheung","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2015.02.031_bib0215","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1172\/JCI42980","article-title":"Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis","volume":"120","author":"Ghosh","year":"2010","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.canlet.2015.02.031_bib0220","doi-asserted-by":"crossref","first-page":"e29671","DOI":"10.1371\/journal.pone.0029671","article-title":"MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer","volume":"7","author":"Donnem","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.02.031_bib0225","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1161\/ATVBAHA.111.236521","article-title":"MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1","volume":"31","author":"Chamorro-Jorganes","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol"},{"key":"10.1016\/j.canlet.2015.02.031_bib0230","doi-asserted-by":"crossref","first-page":"e65153","DOI":"10.1371\/journal.pone.0065153","article-title":"Histone deacetylases and NF-kB signaling coordinate expression of CX3CL1 in epithelial cells in response to microbial challenge by suppressing miR-424 and miR-503","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.02.031_bib0235","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1182\/blood-2009-06-229898","article-title":"miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia","volume":"114","author":"Pallasch","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.02.031_bib0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1756-8722-5-26","article-title":"MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status","volume":"5","author":"Faraoni","year":"2012","journal-title":"J. Hematol. Oncol"},{"key":"10.1016\/j.canlet.2015.02.031_bib0245","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1128\/MCB.02005-06","article-title":"Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression","volume":"27","author":"Linsley","year":"2007","journal-title":"Mol. Cell. Biol"},{"key":"10.1016\/j.canlet.2015.02.031_bib0250","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1038\/sj.onc.1206872","article-title":"PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression","volume":"22","author":"Seminario","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.02.031_bib0255","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.02.031_bib0260","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.leukres.2013.01.021","article-title":"Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors","volume":"37","author":"Breccia","year":"2013","journal-title":"Leuk. Res"},{"key":"10.1016\/j.canlet.2015.02.031_bib0265","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2015.02.031_bib0270","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.22076","article-title":"High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients\u2013systematic review and meta-analysis","volume":"86","author":"Gafter-Gvili","year":"2011","journal-title":"Am. J. Hematol"},{"key":"10.1016\/j.canlet.2015.02.031_bib0275","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1002\/cncr.28328","article-title":"Tolerability and efficacy of pegylated interferon-alpha-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia","volume":"119","author":"Johnson-Ansah","year":"2013","journal-title":"Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515001354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515001354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T01:28:32Z","timestamp":1598750912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383515001354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0304383515001354"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2015.02.031","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Restoration of miR-424 suppresses BCR\u2013ABL activity and sensitizes CML cells to imatinib treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2015.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}